Germantown, Maryland, USA
October 24, 2018
Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the formation of Intrexon Bioinformatics Germany GmbH, a Munich-based bioinformatics company. Now a part of IBG, the Munich-based group of bioinformatics industry leaders have developed software tools focused on mapping genomic, transcriptomic, and epigenomic function in eukaryotic microbes and multicellular organisms employing diverse experimental inputs (microarray, ChipSeq, and Next-Gen Sequencing (NGS)). Their bioinformatics software solutions are designed to enable scientists to develop a robust model of biological "reality" from which to design both Discovery and Applied Research experiments.
"For the last 20 years, the German bioinformatics team has developed award-winning software tools and managed global services for mapping and analyzing complex eukaryotic genomes. Because Intrexon is a leader in the development of targeted, controllable, and multigenic gene networks for the reprogramming of cells and organisms, we are honored to have this highly experienced team expand and improve our library of genetic regulatory components focused on human therapeutics and animal science," said Thomas Reed, PhD, Founder and Chief Science Officer of Intrexon.
Klaus May, PhD, leader of the Munich based team, stated, "We are very proud of our team's rich scientific history, pioneering the analysis and understanding of eukaryotic gene regulation. Our bioinformatics team has published more than 160 peer reviewed scientific papers in journals like Cell, Nature, and Science and generated more than 6,000 citations, and we've supported over 30,000 global customers."
Dr. May added, "I am very excited about the fantastic opportunity of being a part of the Intrexon family because our scientific team can now directly contribute to the design of advanced therapeutic products and food animals with traits focused on biosustainable improvements in productivity and disease resistance. While we will continue to offer a subset of our online software tools to the larger scientific community, we are pleased to announce that our scientists will employ our proprietary database and tools to identify disease targets, suggest therapeutic interventions, and design the regulatory components (promoters, enhancers, and other inter- and intra-genomic regulatory elements) to augment Intrexon's existing technology platforms."
Topics
Species
